Ferric carboxymaltose

Drug Profile

Ferric carboxymaltose

Alternative Names: Ferinject; Injectafer; Iron-dextri-maltose; Iroprem; Renegy; VIT-45; Z-213

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vifor
  • Developer Luitpold Pharmaceuticals; Vifor; Zeria
  • Class Antianaemics; Heavy metals; Iron compounds
  • Mechanism of Action Iron replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Iron deficiency anaemia
  • Phase III Chronic heart failure; Restless legs syndrome

Most Recent Events

  • 20 Jul 2017 Chemical structure information added
  • 01 Jun 2017 Luitpold Pharmaceuticals completes a phase II trial in Iron deficiency anaemia (In adolescents, In children, In infants) in Russia and Poland (IV, Injection, Infusion) (NCT02410213)
  • 24 May 2017 Luitpold Pharmaceuticals initiates a phase II trial for Restless legs syndrome in patients with Iron deficiency anaemia in USA (IV, Infusion) (NCT02826681)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top